<DOC>
	<DOCNO>NCT01908478</DOCNO>
	<brief_summary>This Phase I Study veliparib ( ABT-888 ) combination Gemcitabine Intensity Modulated Radiation Therapy Patients Locally Advanced , Unresectable Pancreatic Cancer . Primary Objectives : - Determine maximum tolerable dose veliparib combination gemcitabine intensity modulate radiation therapy patient locally advanced pancreatic cancer . - Determine safety toxicity combination veliparib gemcitabine radiation therapy patient locally advanced pancreatic cancer</brief_summary>
	<brief_title>A Phase I Study Veliparib ( ABT-888 ) Combination With Gemcitabine Intensity Modulated Radiation Therapy Patients With Locally Advanced , Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>Gemcitabine administer intravenous infusion 1000 mg/m2 30 minute day 1 , 8 , 15 cycle . Intensity modulate radiation therapy ( IMRT ) give total dose 36 Gy 15 fraction ( 2.4 Gy per fraction , one fraction per day , 5 fraction per week , Monday Friday ) begin day 1 . Veliparib administer per dose escalation schema . The start dose veliparib 20 mg BID base upon safety/efficacy data available . Dose escalation continue 20 mg increment maximum tolerate dose ( MTD ) reach . Intra-patient dose escalation allow .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Patients histopathological cytological diagnosis adenocarcinoma pancreas , well high clinical suspicion adenocarcinoma , deem locally advanced unresectable borderline resectable determine pancreatic cancer surgeon and/or follow evaluation GI oncology tumor board . Age 18 year old Patients prior anticancer treatment disease Patients currently receive investigational agent Metastatic disease History allergic reaction attribute compound similar chemical biologic composition PARP [ Poly ( ADPribosome ) polymerase ] inhibitor gemcitabine Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>locally advanced</keyword>
	<keyword>unresectable</keyword>
	<keyword>pancreatic</keyword>
	<keyword>pancreas</keyword>
	<keyword>pancreatic adenocarcinoma</keyword>
</DOC>